Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

Evidence-Based Choice of Conditioning Regimen for Hematopoietic Stem Cell Transplantation (HSCT) in Acute Leukemia: The Italian Cellular Therapy and Stem Cell Transplant Group (GITMO) Guidelines

Blood (2024) 144 (Supplement 1): 2126.

https://doi.org/10.1182/blood-2024-204924

Published: 2024

Journal Articles

Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2024-194632

Published: 2024

Journal Articles

Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 749.

https://doi.org/10.1182/blood-2024-194657

Published: 2024

Journal Articles

Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström's Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)

Blood (2024) 144 (Supplement 1): 3010.

https://doi.org/10.1182/blood-2024-197901

Published: 2024

Journal Articles

Overcoming the Cost Barrier for Thalassemia Innovative Treatments

Angela Vitrano, Rita Barone, Antonino Giangreco, Rosario Di Maggio, Luca Castagna, Gianluca Forni, Emanuele Angelucci, Franco Locatelli, Aurelio Maggio

Blood (2023) 142 (Supplement 1): 5200.

https://doi.org/10.1182/blood-2023-180708

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplants for Patients with Hodgkin disease: A Comparative Study of the LWP EBMT

Blood (2023) 142 (Supplement 1): 4975.

https://doi.org/10.1182/blood-2023-179829

Published: 2023

Journal Articles

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Blood (2023) 142 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2023-185045

Published: 2023

Journal Articles

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2022) 140 (Supplement 1): 6558–6560.

https://doi.org/10.1182/blood-2022-167644

Published: 2022

Journal Articles

CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 7509–7511.

https://doi.org/10.1182/blood-2022-169459

Published: 2022

Journal Articles

Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 7667–7669.

https://doi.org/10.1182/blood-2022-162472

Published: 2022

Journal Articles

Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study

Alberto Mussetti, Abraham S. Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Hervé Finel, Sr., Ariane Boumendil, Sr., Bertram Glass, Luca Castagna, Didier Blaise, Steven G.E. Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Peter Dreger, Stephen R. Spellman, Stephanie J. Lee, Yung-Tsi Bolon, Anna Sureda

Blood (2021) 138 (Supplement 1): 174.

https://doi.org/10.1182/blood-2021-151197

Published: 2021

Journal Articles

Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Michele Malagola, Nicola Polverelli, Massimo Martino, Vicky Rubini, Maria Teresa Lupo Stanghellini, Francesca Patriarca, Renato Fanin, Benedetto Bruno, Luisa Giaccone, Danilo Giuseppe Faraci, Giovanni Grillo, Stefania Bramanti, Luca Castagna, Paolo Bernasconi, Anna Amelia Colombo, Marco De Gobbi, Paolo Nicoli, Annalisa Natale, Stella Santarone, Elisabetta Terruzzi, Attilio Olivieri, Ilaria Scortechini, Patrizia Chiusolo, Elisabetta Metafuni, Angelo Michele Carella, Emanuela Merla, Marco Casini, Irene M Cavattoni, Mario Arpinati, Chiara Nozzoli, Ilaria Cutini, Patrizio Mazza, Annamaria Mazzone, Simona Bassi, Francesco Onida, Giorgia Saporiti, Filippo Antonio Canale, Adriana Vacca, Eugenia Piras, Piero Galieni, Sadia Falcioni, Mario Luppi, Giulia Debbia, Anna Paola Iori, Ursula La Rocca, Vincenzo Pavone, Anna Mele, Cristina Skert, Francesca Carobolante, Paola Carluccio, Carlo Borghero, Francesca Elice, Anna Proia, Fulvia Fanelli, Carmine Selleri, Nicoletta Sacchi, Sonia Mammoliti, Elena Oldani, Fabio Ciceri, Francesca Bonifazi, Domenico Russo

Blood (2021) 138 (Supplement 1): 1786.

https://doi.org/10.1182/blood-2021-145970

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Blood (2021) 138 (Supplement 1): 3890.

https://doi.org/10.1182/blood-2021-151087

Published: 2021

Journal Articles

Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1)

Mohamed A. Kharfan-Dabaja, Myriam Labopin, Ernesto Ayala, Ali Bazarbachi, Didier Blaise, Yener Koc, Jan Vydra, Alessandro Busca, Luca Castagna, Yana Novis, Andrew McDonald, Claude-Eric Bulabois, Christoph Schmid, Concepcion Herrera Arroyo, Edouard Forcade, Fabio Ciceri, Jaime Sanz, Arnon Nagler, Mohamad Mohty

Blood (2021) 138 (Supplement 1): 3910.

https://doi.org/10.1182/blood-2021-149651

Published: 2021

Journal Articles

Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-137099

Published: 2020

Journal Articles

Successful Clearance of Donor Specific Anti-HLA Antibodies after Desensitization with Rituximab, Velcade and Plasma-Exchange Followed By a Haploidentical Stem Cell Transplantion with Post-Transplantation Cyclophosphamide

Sabine Furst, Valerio Maisano, MD, Agnes Basire, Angela Granata, MD, Faezeh Legrand, MD, Raynier Devillier, Samia Harbi, Luca Castagna, MD, Christophe Picard, Claude Lemarie, Pharm.D., Christian Chabannon, MD PhD, Didier Blaise, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142473

Published: 2020

Journal Articles

Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Raynier Devillier, Jacques-Emmanuel Galimard, Myriam Labopin, MD, Didier Blaise, MD, Emanuele Angelucci, Luca Castagna, Jiri Pavlu, MDMRCP,FRCPath, Gerard Socie, MDPhD, Massimo Martino, Friedrich Stoelzel, PD, MD, Gesine Bug, Yves Chalandon, MD, Benedetto Bruno, MD, Victoria Potter, MBBS, BSc, FRACP, FRCPA, Eolia Brissot, MDPhD, Bipin N. Savani, MD, Arnon Nagler, MD, Mohamad Mohty, MD PhD

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-140657

Published: 2020

Journal Articles

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-137789

Published: 2020

Journal Articles

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

Giuseppe Lia, PhD, Clara Di Vito, PhD, Marta Tapparo, PhD, Stefania Bruno, Elisa Zaghi, Michela Calvi, Lucia Brunello, Jacopo Mariotti, MD, Lorenzo Comba, Luisa Giaccone, Martina Fascì, Mario Boccadoro, Andrea Evangelista, MSc, Luca Castagna, MD, Giovanni Camussi, Domenico Mavilio, Benedetto Bruno, MD

Blood (2019) 134 (Supplement_1): 598.

https://doi.org/10.1182/blood-2019-126521

Published: 2019

Journal Articles

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Claire Burney, MBBS, Stephen Robinson, MBBS, PhD BSc, Ariane Boumendil, PhD, Hervé Finel, Irma Khvedelidze, Hannah Hunter, MB,FRCPath,MRCP, Xavier Poire, Bruno Lioure, MD, Karl S Peggs, Robin Foà, MD, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Tom Van Meerten, MD PhD, Juan Jose Bargay, Christoph Schmid, MD, Vergote Vibeke, Arnold Ganser, MD, Luca Castagna, MD, Ghulam J. Mufti, Silvia Montoto, MD

Blood (2019) 134 (Supplement_1): 701.

https://doi.org/10.1182/blood-2019-123442

Published: 2019

NARROW

Evidence-Based Choice of Conditioning Regimen for Hematopoietic Stem Cell Transplantation (HSCT) in Acute Leukemia: The Italian Cellular Therapy and Stem Cell Transplant Group (GITMO) Guidelines

Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström's Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)

Overcoming the Cost Barrier for Thalassemia Innovative Treatments

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplants for Patients with Hodgkin disease: A Comparative Study of the LWP EBMT

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia

Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study

Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1)

Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT

Successful Clearance of Donor Specific Anti-HLA Antibodies after Desensitization with Rituximab, Velcade and Plasma-Exchange Followed By a Haploidentical Stem Cell Transplantion with Post-Transplantation Cyclophosphamide

Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only